Our Company
Our mission is to develop life-changing solutions for patients with debilitating eye diseases

Eyevensys is a privately held, clinical-stage biotechnology company. Our first-in-class, non-viral vector gene therapy, sustained drug delivery system offers a new approach to treating major ophthalmic conditions. In particular, degenerative retinal diseases and retinal vascular diseases such as wet AMD and dry AMD. Together, these illnesses account for the vast majority of vision loss around the globe and significantly impact quality of life for patients of all ages.

Revolutionizing the Treatment of Eye Disease

The Eyevensys technology enables therapeutic proteins to be produced inside the eye—by the eye itself—providing long-lasting treatment effects. It works by administering DNA plasmids directly into the ciliary muscle in the eye, using a process called electrotransfection.

Our novel non-viral gene therapy, sustained ocular drug delivery approach is minimally invasive and offers considerable safety and cost advantages over viral vector gene therapies. It is also more convenient than other intraocular drug delivery approaches, which require repeated intravitreal injection or the insertion of implanted devices.

Dollars raised from investors globally
Average years of ophthalmic disease experience among leadership team members

Our History

Eyevensys was founded in 2008 by Francine Behar-Cohen, MD, PhD, Professor of Ophthalmology at Paris Descartes University. 

Our world-class team brings a wealth of knowledge in ophthalmic and rare disease drug discovery, and development experience spanning Big Pharma, biotech, academia, and nonprofit institutions.

Eyevensys is headquartered in Paris, France, with US locations in Cambridge, Massachusetts, and Fort Worth, Texas. The company has raised nearly USD 50 million from European and North American investors.